UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029888
Receipt number R000034139
Scientific Title Clinical efficacy of intraoperative peritoneal lavage cytology in biliary tract cancer
Date of disclosure of the study information 2017/11/10
Last modified on 2020/12/09 23:11:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical efficacy of intraoperative peritoneal lavage cytology in biliary tract cancer

Acronym

Clinical efficacy of intraoperative peritoneal lavage cytology in biliary tract cancer

Scientific Title

Clinical efficacy of intraoperative peritoneal lavage cytology in biliary tract cancer

Scientific Title:Acronym

Clinical efficacy of intraoperative peritoneal lavage cytology in biliary tract cancer

Region

Japan


Condition

Condition

Biliary tract cancer

Classification by specialty

Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The aim of this retrospective multiinstitutional study is to evaluate the clinical efficacy of intraoperative peritoneal lavage cytology (CY) in biliary tract cancer.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Overall survival

Key secondary outcomes

Recurrence free survival
Recurrence site


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

All patients diagnosed with biliary tract cancer based on diagnostic imagings or pathological diagnosis are included in this study.

Key exclusion criteria

Patients with other cancers and deceased patients within perioperative period are excluded.

Target sample size

500


Research contact person

Name of lead principal investigator

1st name Hiroaki
Middle name
Last name Nagano

Organization

Yamaguchi University Graduate School of Medicine

Division name

Department of Gastroenterological, Breast and Endocrine Surgery

Zip code

755-8505

Address

1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan

TEL

0836-22-2264

Email

hnagano@yamaguchi-u.ac.jp


Public contact

Name of contact person

1st name Satoshi
Middle name
Last name Matsukuma

Organization

Yamaguchi University Graduate School of Medicine

Division name

Department of Gastroenterological, Breast and Endocrine Surgery

Zip code

755-8505

Address

1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan

TEL

0836-22-2264

Homepage URL


Email

smatsu@yamaguchi-u.ac.jp


Sponsor or person

Institute

Kansai Hepatobiliary Oncology Group (KHBO)

Institute

Department

Personal name



Funding Source

Organization

Kansai Hepatobiliary Oncology Group (KHBO)

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institute review board, Yamaguchi University Hospital

Address

1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan

Tel

0836222428

Email

clin_res@yamaguchi-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 11 Month 10 Day


Related information

URL releasing protocol

http://ds26.cc.yamaguchi-u.ac.jp/~crc-di/clin_res/homepage/doc/public_format/H29-094.pdf

Publication of results

Published


Result

URL related to results and publications

https://onlinelibrary.wiley.com/doi/10.1002/cnr2.1323

Number of participants that the trial has enrolled

169

Results

Of 169 patients who underwent curative resection, 164 were cytology-negative,
and five were cytology-positive. The incidence of peritoneal metastatic recurrence
was also higher, and overall survival tended to be worse in the cytology-positive
group. In contrast, recurrence-free survival was similar between the cytology-negative
and cytology-positive groups.

Results date posted

2020 Year 05 Month 11 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results

2020 Year 12 Month 06 Day

Baseline Characteristics

Clinicopathological data of patients with BTCs who underwent treatment from January 2013 to January 2016 were collected from 11 institutions in Japan.

Participant flow

One-hundred and sixty nine patients were enrolled in this study.

Adverse events

none

Outcome measures

The difference between patients who underwent curative resection with and without cytology positive in the cumulative incidence of peritoneal metastatic recurrence, recurrence free survival and overall survival. The association between cytology positive and macroscopic peritoneal metastasis.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 11 Month 08 Day

Date of IRB

2017 Year 09 Month 27 Day

Anticipated trial start date

2017 Year 12 Month 16 Day

Last follow-up date

2018 Year 09 Month 30 Day

Date of closure to data entry

2018 Year 09 Month 30 Day

Date trial data considered complete

2018 Year 09 Month 30 Day

Date analysis concluded

2020 Year 06 Month 30 Day


Other

Other related information

To analyze and compare overall survival, recurrence free survival and recurrece site in patients with positive/negative CY.


Management information

Registered date

2017 Year 11 Month 08 Day

Last modified on

2020 Year 12 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034139


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name